Ibogaine Therapy for Addiction
An ibogaine treatment for addiction is an experience like no other. By inducing a dreamlike but conscious state, this form of therapy can reach deeply into the subconscious to penetrate the innermost dimension of oneself, providing the opportunity for deep cognitive evaluation.
These reflections provide insight into healing and help to process core issues that in many cases have led to reactive behaviors such as excessive drug and alcohol use or abuse. It is during this period of intense introspective clarity that feelings of fear, guilt, shame and depression are lifted and replaced with a newfound outlook and positive alignment concerning one’s self and one’s value.
After experiencing their therapeutic journey, guests are encouraged to reflect upon the experience and to externally process and further contemplate their journey. It is during this time that past behavioral patterns, environments and social factors that supported the prior behaviors are identified and goals are set to modify future patterns in support of healthier and happier life choices.
It should be noted that not all entheogenic plant experiences are equally as visionary and as many as 30% may not experience deeply reflective insights during treatment. However, all treatments do have the unique ability to eliminate post-acute withdrawal symptoms and stifle cravings from even the most chronic of chemical dependency cases.
The ibogaine treatment experience is characterized by three distinct phases; the onset of which progresses gradually beginning 30 minutes following administration.
First Phase (4-8 hours) : ACUTE PHASE. The acute phase begins 1 to 3 hours after administration and will typically last 4 to 8 hours. Many report a “panoramic,” mostly visual experience of past memories. It’s often described as a “waking dream state” with varying experiences that may include contact with transcendent beings, passage along a lengthy path or floating. People often report being placed in or entering visual landscapes, rather than experiencing intrusive visual or auditory hallucinations. Not all subjects experience these visual phenomena, which may be related to bioavailability and interindividual variation.
Second Phase (8-18 hours) : EVALUATIVE PHASE. The evaluative phase begins approximately 4 to 8 hours after administration and may last 8 to 18 hours. People often report a more neutral and reflective emotional tone. Attention is directed at evaluating the experiences of the acute phase. Many prefer as little environmental stimuli during this phase and the acute phase as it’s easy to become agitated or annoyed by distractions.
Third Phase (24-48 hours) : RESIDUAL STIMULATION PHASE. The residual stimulation phase begins approximately 8 to 18 hours after administration and can last 24 to 48 hours or more. Attention shifts back to the external environment, normal physical movement returns and people often report heightened arousal and vigilance during this period.